Advertisement Sigma-Aldrich and D-Finitive Cell Technologies form research collaboration - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Sigma-Aldrich and D-Finitive Cell Technologies form research collaboration

Sigma-Aldrich, a life science and high technology company, has entered into a research collaboration program with D-Finitive Cell Technologies, a provider of biomedical research products.

This collaboration is expected to support the development and commercial offering of 14 products over a two-year span, with a planned launch of many of these products in 2009.

These additions to Sigma-Aldrich’s portfolio of research tools for regenerative medicine are expected to consist of serum-free media for bone marrow and umbilical cord stem cells, mesenchymal stem cells and neural stem cells; cytokine cocktails for stem cell expansion and differentiation; novel formulations for cyropreservation of stem cells; and specialized products to conduct clonogenic assays of the various stem cells.

Carl Schrott, marketing director for regenerative medicine at Sigma-Aldrich, said: “We are excited about this collaboration. Working with biotech companies such as D-Finitive enables us to commercialize more products as a complement to our in-house product development.”